Management of crash and burn patients with SARS-CoV-2 associated ARDS

J Card Surg. 2020 Sep;35(9):2129-2130. doi: 10.1111/jocs.14699. Epub 2020 Jul 14.

Authors

Ali Ghodsizad^{1

2}, April A Grant³, Mehdi Mirsaeidi⁴, Waleed C Sneij⁴, Laiqua Khalid⁴, David Delazerda⁴, Jonathan S Auerbach⁴, Roger A Alvarez⁴, Eduardo J de Marchena⁵, Joshua Hare⁵, Giselle Guerra⁶, Rodrigo Vianna^{1

2}, Matthias Loebe^{1

2}

Affiliations

¹ Heart and Lung Transplant and Mechanical Circulatory Support, Miller School of Medicine, University of Miami, Miami, Florida.
² Heart and Lung Transplant and Mechanical Circulatory Support, Miami Transplant Institute, Miami, Florida.
³ School of Medicine and Grady Hospital System, Emory University, Atlanta, Georgia.
⁴ Pulmonary Critical Care, Miller School of Medicine, University of Miami, Miami, Florida.
⁵ Department of Cardiology, Miller School of Medicine, University of Miami, Miami, Florida.
⁶ Department of Nephrology, Miller School of Medicine, University of Miami, Miami, Florida.

No abstract available

Keywords: COVID-19; MSCS; immunoglobulin; stem cells.

Publication types

Editorial

MeSH terms

Adult Stem Cells / transplantation
Angiotensin-Converting Enzyme 2 / therapeutic use
Azithromycin / therapeutic use
Blood Component Transfusion
COVID-19 / complications
COVID-19 / therapy*
Extracorporeal Membrane Oxygenation / methods
Humans
Hydroxychloroquine / therapeutic use
Ivermectin / therapeutic use
Plasma
Recombinant Proteins / therapeutic use
Respiratory Distress Syndrome / therapy*
Respiratory Distress Syndrome / virology*
SARS-CoV-2

Substances

Recombinant Proteins
Hydroxychloroquine
Ivermectin
Azithromycin
ACE2 protein, human
Angiotensin-Converting Enzyme 2